Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | M-Exempt | 6,000 @ $58.84 | $353.0K |
Daily · Wilder smoothing
| Sep 29, 26 |
| Sandler Alan B. |
| officer: Chief Development Officer |
| M-Exempt |
| 6,000 @ $58.84 |
| $353.0K |
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | S-Sale | 2,200 @ $200.82 | $441.8K |
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | S-Sale | 1,609 @ $201.72 | $324.6K |
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | S-Sale | 1,000 @ $202.81 | $202.8K |
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | S-Sale | 1,199 @ $203.91 | $244.5K |
| Sep 29, 26 | Sandler Alan B. | officer: Chief Development Officer | S-Sale | 301 @ $204.72 | $61.62K |
| Sep 25, 26 | Cislini Jeff | officer: SVP & General Counsel | S-Sale | 765 @ $207.32 | $158.6K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.85 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 41.88 | Oscillator | Neutral |
| Williams %R (14) | -62.10 | Oscillator | Neutral |
| MACD (12, 26, 9) | -3.45 (Hist -0.26) | Oscillator | Strong Sell |
| Average Directional Index (14) | 20.94 (+DI 20.0 / -DI 27.0) | Trend | Sell |
| EMA 20 | 193.15 | MA | Sell |
| SMA 20 | 195.12 | MA | Strong Sell |
| EMA 50 | 195.10 | MA | Strong Sell |
| SMA 50 | 201.60 | MA | Strong Sell |
| SMA 200 | 154.26 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 13, 2026 | 2026-10-13 16:32:09 | View |
| 4 | Oct 1, 2026 | 2026-10-01 18:00:04 | View |
| 4 | Sep 29, 2026 | 2026-09-29 18:00:09 | View |
| 4 | Sep 28, 2026 | 2026-09-28 18:00:04 | View |
| 4 | Sep 24, 2026 | 2026-09-24 18:00:04 | View |
| 4 | Sep 22, 2026 | 2026-09-22 18:00:03 | View |
| 4 | Sep 18, 2026 | 2026-09-18 18:06:03 | View |
| 4 | Sep 18, 2026 | 2026-09-18 18:05:04 | View |
| 4 | Sep 18, 2026 | 2026-09-18 18:04:03 | View |
| 4 | Sep 18, 2026 | 2026-09-18 18:03:05 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | RVMD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -21.2x | -10.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -19.8x | EPS est. -9.49 | In line |
| Price / Book | 15.2x | 4.0x | Elevated |
| Price / Sales | — | 79.4x | Discount |
| EV / EBITDA | -23.8x | -9.8x | Elevated |
| Return on equity | -96.4% | — | Weak |
| Gross margin | 0.0% | 60.0% | Below hist. |
| Debt / Equity | 0.25 | 0.08 | Conservative |
| Piotroski / Altman Z | 1/9 | Z 12.49 | Safe zone |
Discounted cash flow model
Current price $188.19
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 21, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 19, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 15, 26 | Needham | maintain | Buy | Buy |
| Oct 14, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 7, 26 | Truist Securities | maintain | Buy | Buy |
| Sep 21, 26 | B of A Securities | maintain | Buy | Buy |
| Sep 9, 26 | Stifel | maintain | Buy | Buy |
| Aug 31, 26 | Needham | maintain | Buy | Buy |
FY2022 · 10-K disclosure
Stock news · updated daily
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that exploratory subgroup analyses from the Phase 3 RASolute 302 trial were presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The analyses showed that RASONQUE (daraxonrasib) consistently provided an overall survival (OS) benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma (PDAC), including those with no identified tumor RAS mutation. The OS benefit with RASONQUE was also maintained across preselected standard-of-care (SOC) chemotherapy regimens and prior treatment settings, including early metastatic recurrence following perioperative therapy.
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -2.04 | -3.06 | Miss -50.0% | — |
| May 6, 2026 | -1.84 | -2.29 | Miss -24.5% | — |
| Feb 25, 2026 | -1.58 | -1.86 | Miss -17.7% | — |
| Nov 5, 2025 | -1.42 | -1.61 | Miss -13.4% | — |
| Aug 6, 2025 | -1.14 | -1.31 | Miss -15.1% | — |
| May 7, 2025 | -1.12 | -1.13 | Miss -0.9% | — |